Clinical Trial Update: The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study assesses the safety and tolerability of a subcutaneous dose of STSA-1301 in healthy subjects; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• STSA-1301

Snippet

Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd | Conditions: Primary Immune Thrombocytopenia | Phase 1 | Status: COMPLETED